D.E. Shaw & Co
AVBP icon

D.E. Shaw & Co’s ArriVent BioPharma AVBP Stock Holding History

D.E. Shaw & Co’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.3M Buy
872,011
+503,216
+136% +$14.9M 0.01% 1039
2026
Q1 		$8.51M Buy
368,795
+135,471
+58% +$3.06M 0.01% 1773
2025
Q4 		$4.69M Buy
+233,324
New +$4.86M ﹤0.01% 2359
2024
Q4 		– Sell
-8,775
Closed -$206K – 4963
2024
Q3 		$206K Buy
+8,775
New +$199K ﹤0.01% 4143

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co's AVBP Position: Q2 2026 in Review

D.E. Shaw & Co increased its ArriVent BioPharma (AVBP) stake by 136% in Q2 2026, buying an estimated $14.9M and bringing the position to 872,011 shares worth $30.3M. The position accounts for 0.01% of the portfolio, ranked #1039.

D.E. Shaw & Co first reported a position in AVBP in Q3 2024 and has held it in 4 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • D.E. Shaw & Co held 872,011 shares of ArriVent BioPharma worth $30.3M as of Q2 2026.
  • D.E. Shaw & Co bought 503,216 ArriVent BioPharma shares in Q2 2026, an estimated $14.9M.
  • ArriVent BioPharma made up 0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #1039 holding.
  • D.E. Shaw & Co first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 4 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.